Results 241 to 250 of about 2,455,455 (282)

Limitations of Reporting Time Below Range as a Percentage

Diabetes Technology & Therapeutics, 2023
Continuous glucose monitoring (CGM)-based metrics such as time in range and time below range (TBR) and their clinical targets are recommended along with glycated hemoglobin (A1c) to optimize diabetes care. CGM metrics are easy to understand by people with diabetes and have been widely accepted among health care providers. TBR, that is, time spent below
Viral N Shāh
openaire   +4 more sources

Glucose Time In Range, Time Above Range, and Time Below Range Depend on Mean or Median Glucose or HbA1c, Glucose Coefficient of Variation, and Shape of the Glucose Distribution

Diabetes Technology & Therapeutics, 2020
Background: Examine the expected relationships between time in range (%TIR), time above range (%TAR), and time below range (%TBR) with median glucose (or %HbA1c) and %coefficient of variation (%CV) of glucose for various shapes of the glucose distribution.
David Rodbard
openaire   +4 more sources

Time in Tight Range (TITR) stratified by Time Below Range (TBR) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study

Acta Diabetologica
To analyze the Time in Tight Range (TITR) (70-140 mg/dL) and assess their possible differences according to Time Below Range (TBR) in a cohort of type 1 diabetes mellitus people with Múltiple Daily Injections.355 adult users of Continuous Glucose Monitoring (CGM) with at least a HbA1c during the period October 1, 2023-October 1, 2024, and glucose data ...
Sandra Herranz-Antolín   +6 more
openaire   +4 more sources

Time below Range

International Journal of Diabetes and Technology, 2022
Background: Patients with diabetes mellitus (DM) need to be regularly monitored for analyzing their levels of glycemic control as well as for ruling out the risk of hypoglycemia. Assessing the time in range (TIR) (70–180 mg/dL) is a novel measure of pointing out these risks.
Manoj Chawla   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy